ProCE Banner Activity

Key Takeaways and Expert Answers: SGLT2 Inhibitors in Heart Failure Management

Clinical Thought

Explore key takeaways and expert answers to common questions from a symposium on SGLT2 inhibitors in heart failure. Learn about their effectiveness, cost management strategies, and the potential of combining with GLP-1 receptor agonists for some patients.

Released: December 10, 2024

Expiration: December 09, 2025

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Ty J. Gluckman

Ty J. Gluckman, MD, MHA

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, Adaptyx, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Bearing, CVRx, Cytokinetics, Edwards, Faraday, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, Medtronics, Merck, Owkin, Novartis, Novo Nordisk, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Secretome, Vifor, Zoll.

Ty J. Gluckman, MD, MHA

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ty J. Gluckman, MD, MHA, has no relevant financial relationships to disclose.